RAPID MICRO BIOSYSTEMS, INC.RPIDEarnings & Financial Report
Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.
Revenue
$7.8M
Gross Profit
N/A
Operating Profit
$-11.4M
Net Profit
$-11.5M
Gross Margin
N/A
Operating Margin
-145.1%
Net Margin
-146.8%
YoY Growth
3.1%
EPS
$-0.26
RAPID MICRO BIOSYSTEMS, INC. Q3 FY2025 Financial Summary
RAPID MICRO BIOSYSTEMS, INC. reported revenue of $7.8M (up 3.1% YoY) for Q3 FY2025, with a net profit of $-11.5M (down 1.6% YoY) (-146.8% margin).
Key Financial Metrics
| Total Revenue | $7.8M |
|---|---|
| Net Profit | $-11.5M |
| Gross Margin | N/A |
| Operating Margin | -145.1% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
RAPID MICRO BIOSYSTEMS, INC. Q3 FY2025 revenue of $7.8M breaks down across 2 segments, led by Recurring Contract With Customer at $4.8M (61.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Recurring Contract With Customer | $4.8M | 61.7% |
| Non Recurring Contract With Customer | $3.0M | 38.3% |
RAPID MICRO BIOSYSTEMS, INC. Annual Revenue by Year
RAPID MICRO BIOSYSTEMS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $33.6M |
| 2024 | $28.1M |
| 2023 | $22.5M |
| 2022 | $17.1M |
RAPID MICRO BIOSYSTEMS, INC. Quarterly Revenue & Net Profit History
RAPID MICRO BIOSYSTEMS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.3M | +37.3% | $-12.5M | -110.8% |
| Q3 FY2025 | $7.8M | +3.1% | $-11.5M | -146.8% |
| Q2 FY2025 | $7.3M | +9.7% | $-11.9M | -163.3% |
| Q1 FY2025 | $7.2M | +28.4% | $-11.3M | -156.3% |
| Q4 FY2024 | $8.2M | +29.7% | $-9.7M | -117.6% |
| Q3 FY2024 | $7.6M | +23.7% | $-11.3M | -148.9% |
| Q2 FY2024 | $6.6M | +32.3% | $-12.6M | -190.1% |
| Q1 FY2024 | $5.6M | +11.4% | $-13.3M | -237.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.6M | $6.6M | $7.6M | $8.2M | $7.2M | $7.3M | $7.8M | $11.3M |
| YoY Growth | 11.4% | 32.3% | 23.7% | 29.7% | 28.4% | 9.7% | 3.1% | 37.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $127.7M | $117.1M | $105.8M | $98.2M | $85.4M | $75.6M | $84.4M | $74.9M |
| Liabilities | $21.8M | $22.5M | $21.5M | $22.8M | $19.9M | $21.0M | $40.1M | $41.6M |
| Equity | $105.9M | $94.6M | $84.4M | $75.4M | $65.5M | $54.5M | $44.3M | $33.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.5M | $-10.1M | $-8.6M | $-9.9M | $-9.1M | $-9.7M | $-9.1M | $-3.2M |